{
    "clinical_study": {
        "@rank": "45041", 
        "arm_group": [
            {
                "arm_group_label": "Eryfotona AK-NMSC\u00ae cream", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Sunscreen SPF 50+", 
                "arm_group_type": "Other"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy, safety and tolerability of Eryfotona\n      AK-NMSC\u00ae topical application vs Sunscreen on cancerization field of actinic keratosis\n      patients after 6 months of treatment."
        }, 
        "brief_title": "Long Term Efficacy and Safety of Eryfotona AK-NMSC\u00ae in Patients With Actinic Keratosis", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Actinic Keratosis", 
        "condition_browse": {
            "mesh_term": [
                "Keratosis", 
                "Keratosis, Actinic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Current diagnosis of AK, with \u22654 lesions located in the same anatomical  district\n             (within a contiguous 50 cm2 area on the face, bold scalp or forehead);\n\n          2. Female or male >18 years of age;\n\n          3. Skin type I or II according to Fitzpatrick;\n\n          4. Patient has confirmed his/her willingness to participate in this study;.\n\n        Exclusion Criteria:\n\n          1. Topical drug therapy for AK within the past 3 months or for photoaging in the last 6\n             months, or had lesion-directed therapy within 2 cm2 of the selected AK area during\n             the previous month;\n\n          2. Suitable for surgical, photodynamic or any other topical treatment in the next 6\n             months;\n\n          3. Subjects who suffer/ had suffered from skin cancer or show an early stage of skin\n             cancer or have a genetic predisposition for skin cancer;\n\n          4. Other skin disease that requires treatment with other medications in the treatment\n             area or in the distance of 3 cm;\n\n          5. Immunosuppression or current treatment for cancer;\n\n          6. Clinically unstable medical condition;\n\n          7. High risk group for HIV infection or presentation of other infectious diseases\n\n          8. Presentation of contact allergies or allergies to compounds of the test substances;\n\n          9. Smoker (more than forty cigarettes per day) or heavy drinker (more than three\n             standard drinks per day);\n\n         10. Psychiatric disease that may interfere with follow up of study procedures;\n\n         11. Participation in other clinical trials up to 30 days prior to day 1 of the study\n\n         12. Prior treatment with study medication in the area to be treated;\n\n         13. Considered by the investigator, for any other reason, to be an unsuitable candidate\n             for the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01656226", 
            "org_study_id": "ISD-FPT-01-2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "Eryfotona AK-NMSC\u00ae cream", 
                "description": "Cream, to be applied according to COLIPA standard at 2 mg/cm\u00b2 in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.", 
                "intervention_name": "Eryfotona AK-NMSC\u00ae cream", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Sunscreen SPF 50+", 
                "description": "Cream, to be applied according to COLIPA standard at 2 mg/cm\u00b2 in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.", 
                "intervention_name": "Sunscreen SPF 50+", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sunscreening Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Actinic Keratosis", 
            "AK"
        ], 
        "lastchanged_date": "October 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Reggio Emilia", 
                    "country": "Italy"
                }, 
                "name": "Dermatology Unit, Medical Department Arcispedale Santa Maria Nuova"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised Double-blind Parallel-group Study to Evaluate the Long-term Effects of Eryfotona AK-NMSC\u00ae Cream in the Treatment of Cancerization Field in Patients With Actinic Keratosis.", 
        "overall_official": {
            "affiliation": "Dermatology Unit, Medical Department /Arcispedale Santa Maria Nuova /Reggio Emilia, Italy", 
            "last_name": "Dr. Giuseppe Argenziano, , MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Comparison between treatment groups at the end of the treatment period", 
            "measure": "Percentage of patients with partial clearance of AK lesions", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01656226"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Comparison between treatment groups at the end of the treatment period", 
                "measure": "Percentage of patients with clearance and improvement of AK lesions", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Comparison between treatment groups at the end of the treatment period", 
                "measure": "Total number of AK lesions in the treated area (including all lesions present at baseline as well as subclinical lesions which appeared during therapy)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Comparison between treatment groups at the end of the treatment period", 
                "measure": "Percentage of patients with improvement (clinical and dermoscopic assessment) of the target area as for the erythema, scaling, pigmentation and follicular plugs", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Comparison between treatment groups at the end of the treatment period", 
                "measure": "Percentage of patients with changes in the Investigator Global Improvement Index", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Comparison between treatment groups at the end of the treatment period", 
                "measure": "Percentage of patients with changes in Baseline Severity Index (BSI)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Comparison between treatment groups at the end of the treatment period", 
                "measure": "Percentage of patients with improvement in the target AK lesion by using RCM score.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Comparison between treatment groups at the end of the treatment period Validation of a new RCM score", 
                "measure": "Percentage of patients with improvement in the \"cancerization filed\" by RCM score", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Comparison between treatment groups at the end of the treatment period", 
                "measure": "Percentage of patients compliant to treatment", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Comparison between treatment groups over time and at the end of the treatment period", 
                "measure": "Percentage of patients which report satisfaction to local tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Comparison between treatment groups over time and at the end of the treatment period", 
                "measure": "Number of patients with AEs and local AEs (skin reactions)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Comparison between treatment groups at the end of the treatment period", 
                "measure": "Percentage of patients which report satisfaction to treatment", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "ISDIN", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ISDIN", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}